Hallucinations in schizophrenia are a relatively common clinical symptom, often manifesting as patients can hear or feel voices appearing in their heads, but no such stimuli occur in reality, and those around them are unable to feel this pathological feeling of the patient. Hallucinations in schizophrenia are associated with increased concentrations of dopamine in the synaptic gap, so antipsychotic medication is the preferred clinical treatment. Three generations of antipsychotic drugs have been developed to treat the symptoms of hallucinations. The first generation of antipsychotics, also known as traditional antipsychotics, are commonly used, such as chlorpromazine and fenadine. The second generation of antipsychotics, also known as atypical antipsychotics, are equivalent to the first generation in terms of therapeutic effectiveness, but with significantly fewer relative side effects. Common drugs include olanzapine, quetiapine and others. Third-generation antipsychotics currently have a different mechanism of action than the first two generations and can exhibit partial agonism of some dopamine receptors. It can be more effective in improving is some negative symptoms of schizophrenia, and also has a good effect on the common symptoms of schizophrenia such as hallucinations and hallucinations, for example, aripiprazole. Therefore, the treatment of schizophrenia’s hallucinatory symptoms must be based on the selection of appropriate antipsychotic drugs and a full dose and course of treatment.